StarOne IP v. Axlab & BiopSafe: Formalin Container Patent Dismissed Without Prejudice
StarOne Intellectual Property Group Ltd. filed suit against Axlab Inc., Axlab A/S, and BiopSafe ApS in the Northern District of Illinois, asserting US7475774B2 against the BiopSafe® Formalin Safety Container product line. The action was voluntarily dismissed without prejudice after 174 days — leaving the door open for future enforcement.
Formalin container patent suit ends in voluntary exit — but case stays open
StarOne Intellectual Property Group Ltd., a dedicated IP holding entity, filed this infringement action on 24 May 2024 in the Northern District of Illinois before Judge Manish S. Shah. The suit named three defendants: U.S. entity Axlab Inc. and its Danish counterparts Axlab A/S and BiopSafe ApS. At issue was US7475774B2, a patent covering formalin safety container technology, asserted against BiopSafe® Formalin Safety Containers in 20 ml and 60 ml configurations (model nos. 3178-20000 and 3178-60000).
On 14 November 2024 — 174 days after filing — StarOne invoked Federal Rule of Civil Procedure 41(a)(1) to voluntarily dismiss the action without prejudice. A Rule 41(a)(1) dismissal requires no court approval when filed before the defendant serves an answer or motion for summary judgment, and the public record does not indicate either had been served at the time. Critically, dismissal without prejudice means StarOne retains the right to refile the same claims in a future action, subject to applicable statutes of limitations.
The swift resolution — under six months with no substantive rulings — is consistent with early-stage settlements, licensing negotiations, or a strategic reassessment of claim scope. The public record is silent on whether any agreement was reached between the parties. The absence of any fee award or sanction order suggests the dismissal was uncontested. Companies operating in specimen-preservation and histology supply markets should note that the underlying patent remains active and the infringement claims have not been adjudicated on the merits.
Filing to Voluntary dismissal in 174 days
174 days — resolved before any substantive court rulings or claim construction
Voluntarily dismissed: what the Rule 41(a)(1) exit means for both parties
Rule 41(a)(1): plaintiff-initiated exit, no court order required
Federal Rule of Civil Procedure 41(a)(1) permits a plaintiff to dismiss an action as of right by filing a notice before the defendant serves an answer or a motion for summary judgment. No judicial approval is needed, and the dismissal takes effect immediately upon filing. This mechanism is commonly used when parties reach an informal resolution or when plaintiff elects to pause litigation strategically, without surrendering future rights.
No merits adjudicationThe public record does not specify — and the distinction matters
A dismissal ‘without prejudice’ preserves the plaintiff’s right to refile the same claims. A dismissal ‘with prejudice’ extinguishes them permanently. The verdict text here states ‘without prejudice’ explicitly, meaning StarOne retains refiling rights. However, a second voluntary dismissal of the same claims against the same defendants would operate as an adjudication on the merits under Rule 41(a)(1)(B) — the so-called ‘two-dismissal rule’ — a risk StarOne would need to weigh in any future action.
Refiling risk: two-dismissal ruleAxlab and BiopSafe exit without a liability finding — but uncertainty remains
The three defendants avoided any finding of infringement, injunction, or damages award. No cost or fee award in their favour is recorded, which suggests the departure was procedurally clean. That said, the without-prejudice dismissal provides no legal insulation against future suit on the same patent. Defendants in the formalin container supply chain should consider whether their freedom-to-operate position is sufficiently documented in the event of a refiled action.
No liability found — not immune from refilingUS7475774B2 remains live — sector-wide FTO exposure persists
The without-prejudice dismissal leaves US7475774B2 fully enforceable. Any competitor manufacturing, importing, or distributing formalin safety containers in the United States faces ongoing exposure to this patent until its expiry or a successful validity challenge. The case signals that StarOne is actively monitoring the market. Histology and specimen-preservation equipment suppliers should review their product designs against the claims of US7475774B2 now, rather than await a new filing.
Patent remains enforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | StarOne Intellectual Property Group Ltd. | Company | IP holding entity — asserting US7475774B2 covering formalin safety containersSearch in Eureka ↗ |
| Defendant | Axlab Inc. | Company | Axlab Inc. (US), Axlab A/S and BiopSafe ApS (Denmark) — makers of BiopSafe® formalin containersSearch in Eureka ↗ |
| Co-Defendant | Axlab A/S | Individual | Search in Eureka ↗ |
| Co-Defendant | BiopSafe ApS | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Craig L. Uhrich | Attorney | Counsel for StarOne Intellectual Property Group Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Craig L. Uhrich, ESQ. | Law Firm | Representing StarOne Intellectual Property Group Ltd.Search in Eureka ↗ |
| Defendant counsel | Mark Andrew Borsos. | Attorney | Counsel for Axlab Inc.Search in Eureka ↗ |
| Defendant law firm | Fitch Even Tabin & Flannery, LLP | Law Firm | Representing Axlab Inc.Search in Eureka ↗ |
| Presiding judge | Judge Manish S. Shah | Judge | Illinois Northern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1), the plaintiff’s unilateral right to exit before a responsive pleading is served. The explicit ‘without prejudice’ designation is legally significant: it preserves StarOne’s right to refile identical infringement claims against any or all defendants. No liability, no damages, and no injunctive relief were granted or denied. The absence of a fee motion by defendants is consistent with an uncontested departure. For US7475774B2, this ruling establishes no precedent on validity or infringement scope.
US7475774B2 — Formalin Safety Container Technology
US7475774B2, filed under application number US10/570599, covers formalin safety container technology used in the preservation of biological specimens — a critical step in histopathology and diagnostic workflows. Formalin (formaldehyde solution) is a hazardous fixative; safety containers are engineered to minimise exposure risk during specimen collection, transport, and laboratory handling. The patent’s technical focus on containment and safety design reflects regulatory and occupational-health pressures in clinical and pathology settings.
For laboratory supply companies, US7475774B2 represents a potentially blocking position over a commodity-adjacent product category where design differentiation is limited. The BiopSafe® product line — a branded, commercially distributed offering sold in multiple volume configurations — suggests the patent covers commercially significant design features rather than niche applications. Any manufacturer or distributor of formalin containers targeting the U.S. market should treat this patent as a live enforcement risk given StarOne’s demonstrated willingness to assert it.
Should you run an FTO analysis against US7475774B2?
Any company designing, manufacturing, importing, or distributing formalin safety containers for the U.S. clinical or research laboratory market should assess their freedom-to-operate against US7475774B2. The patent remains enforceable, no court has narrowed its claims, and the plaintiff has expressly preserved refiling rights. This applies with particular urgency to suppliers whose products overlap with the 20 ml or 60 ml configurations that were specifically accused in this litigation.
PatSnap Eureka’s FTO Search Agent can map the independent and dependent claims of US7475774B2 against your product specifications, surface relevant prior art that could support a validity challenge, and identify design-around opportunities. Eureka can also flag related family members and continuations that may extend the risk perimeter beyond the single asserted patent — giving your R&D and legal teams a complete picture before a new enforcement action is filed.
Run a freedom-to-operate analysis on US7475774B2 to assess your product’s exposure
Run FTO in Eureka →Similar patent cases: formalin containers and laboratory supply IP in U.S. district courts
Cases involving laboratory specimen-preservation device patents litigated in U.S. district courts — particularly disputes over safety container designs and medical consumable IP.
What this case signals for the specimen-preservation and laboratory supply IP landscape
A voluntary exit inside six months — with no merits ruling — rarely signals the end of an enforcement story.
Without-prejudice dismissals are often a pause, not a conclusion
When a plaintiff invokes Rule 41(a)(1) this early — before any claim construction or responsive pleading — it typically signals ongoing negotiation, a licensing discussion, or a tactical reset rather than abandonment. Competitors and supply-chain partners of Axlab and BiopSafe should treat US7475774B2 as an active enforcement threat until expiry or invalidation.
Multi-entity defendant structures complicate future enforcement calculus
Naming both U.S. and Danish entities (Axlab Inc., Axlab A/S, BiopSafe ApS) suggests StarOne was attempting to capture the full corporate structure behind the BiopSafe product line. If litigation resumes, jurisdictional and service-of-process questions for the Danish entities may become material. Companies with overseas parents operating in the U.S. market should assess their structural exposure.
StarOne v Axlab — key questions answered
StarOne dismissed its infringement claims under Rule 41(a)(1) without prejudice, meaning no court adjudicated the merits and StarOne retains the right to refile the same claims against Axlab Inc., Axlab A/S, and BiopSafe ApS in a future action. No liability finding, damages, or injunction was issued.
StarOne asserted US7475774B2 (application no. US10/570599), a patent covering formalin safety container technology, against the BiopSafe® Formalin Safety Containers in 20 ml (model 3178-20000) and 60 ml (model 3178-60000) configurations.
Yes. A Rule 41(a)(1) dismissal without prejudice preserves plaintiff’s right to refile. However, a second voluntary dismissal of the same claims against the same defendants would constitute an adjudication on the merits under the ‘two-dismissal rule’ (Rule 41(a)(1)(B)), which StarOne would need to account for strategically.
The case was dismissed before any substantive ruling, so there is no finding in favour of any party. Axlab and BiopSafe avoided a liability determination, but the without-prejudice dismissal provides no legal bar against future infringement claims on US7475774B2.
The case (No. 1:24-cv-04315) was filed in the Northern District of Illinois and assigned to Judge Manish S. Shah. It was filed on 24 May 2024 and closed on 14 November 2024 after 174 days, ending via voluntary dismissal without prejudice.
PatSnap Eureka searches patents and litigation data to answer instantly.